1 / 6

FORTISSIMO study

FORTISSIMO study. Benefits of the treatment of uncontrolled hypertension by perindopril/indapamide fixed full-dose combination. Karpov YA; FORTISSIMO program. Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy. Objectives.

ikia
Download Presentation

FORTISSIMO study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FORTISSIMO study Benefits of the treatment of uncontrolled hypertension by perindopril/indapamide fixed full-dose combination KarpovYA; FORTISSIMO program.Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

  2. Objectives • Evaluate the safety and efficacy of the fixed-dose combination perindopril arginine/indapamide (10/2.5 mg) in reaching the blood pressure target • In patients withuncontrolled hypertension • With previous treatment: fixed or free combination of renin-angiotensin-aldosterone system (RAAS) inhibitors + hydrochlorothiazide (HCTZ) Karpov YA; FORTISSIMO program.Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

  3. Design and Methods • Open, prospective, multicenter, observational, noncomparative study • Inclusion criteria: uncontrolled hypertension (160-200 mm Hg) • 2120 hypertensive ambulatory patients in 35 regions of Russia • 12-week study (5 visits) • Switch to drug combination perindopril/indapamide (10/2.5 mg) • Assessment of: • Office blood pressure dynamics • Blood and urine assays • Quality of life • Treatment compliance Karpov YA; FORTISSIMO program.Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

  4. Results – Blood pressure • Blood pressure significantly decreased over time • After 3 months of treatment, 84% of patients reached the blood pressure target Karpov YA; FORTISSIMO program.Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

  5. Results - Tolerability • Treatment compliance significantly increased • Only 4% of patients had adverse effects • Biochemical markers showed no negative changes Karpov YA; FORTISSIMO program.Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

  6. Conclusion • Rapid and sustained effect with the drug combination perindopril/indapamide (10/2.5 mg) in patients with uncontrolled hypertension • 84% of patients reached the blood pressure target • Treatment: good tolerability Karpov YA; FORTISSIMO program.Poster presented at:  European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.

More Related